3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
6
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Gastrointestinal Neoplasms
1
GastroEsophageal Cancer
1
Gastric or Gastroesophageal Cancer
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
3
spartalizumab
2
trametinib
1
tislelizumab
1
palbociclib
1
nazartinib
1
milademetan
1
enzalutamide
1
devimistat
1
dehydroftorafur
1
canakinumab
1
binimetinib
1
bemarituzumab
1
aldesleukin
1
Specimen Handling
1
Pentostatin
1
Midazolam
1
Methods
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Interleukin-2
1
IFL protocol
1
Hydroxychloroquine
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Early Intervention, Educational
1
Cyclophosphamide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
bemarituzumab
×
Gastrointestinal
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled